Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of the Commonwealth of Australia, serves to regulate the therapeutic goods industry in order to protect public health by ensuring that the quality, efficacy, and safety of therapeutic goods are maintained. The Act was introduced to address the need for a comprehensive regulatory framework governing therapeutic goods, encompassing their development, manufacture, supply, and advertising. The Act empowers the Therapeutic Goods Administration to oversee the regulation of therapeutic goods, including the issuance of consents for the supply and importation of goods that do not fully comply with certain standards, subject to specific conditions. This ensures that the public can have access to therapeutic goods that meet an acceptable standard of quality, efficacy, and safety. The policy objective of the Therapeutic Goods Act 1989 is to safeguard public health by regulating therapeutic goods in a manner that balances the need for access to safe and effective products with the need to protect consumers from potential harm. This is achieved through the implementation of a risk-based regulatory approach, which involves the assessment and management of risks associated with therapeutic goods throughout their lifecycle. By providing a framework for the regulation of therapeutic goods, the Act aims to foster innovation and support the development of new therapeutic products while ensuring that the health and safety of consumers are prioritised.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation of therapeutic goods in Australia, encompassing the supply, importation, and advertising of such goods. It is a Commonwealth Act, meaning it has jurisdiction across the entire nation. The Act applies to various entities, including manufacturers, importers, sponsors, and suppliers of therapeutic goods, as well as individuals or organisations involved in the advertising of these goods. The Act’s reach extends to therapeutic goods, which include medicines, medical devices, blood, and tissues, ensuring their safety, quality, and efficacy. The Act’s application is comprehensive and includes all therapeutic goods unless specifically excluded by regulations or schedules. Specific exclusions may apply to goods that are regulated under other federal or state laws, but these exclusions are detailed within the Act or its subordinate instruments. The Act can also extend or restrict its application through regulations, which may include detailed standards and conditions for the approval of therapeutic goods.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) provides a regulatory framework for therapeutic goods in Australia. Sections 14 and 14A of the Act allow the Secretary of the Department of Health and Ageing, or their delegate, to give consent for the supply, importation, and other dealings with therapeutic goods under specific conditions (s 14). This consent can permit deviations from certain regulatory standards, as long as the therapeutic goods ultimately meet the necessary safety, quality, and efficacy requirements. For instance, between 13 September 2010 and 8 March 2011, the delegate issued several consents under sections 14 and 14A, each tailored to specific therapeutic goods and their respective Australian Register of Therapeutic Goods (ARTG) numbers. These consents allowed for variations in active ingredient content, labelling requirements, and conformity standards, subject to certain conditions and timeframes. Entities such as Wyeth Consumer Healthcare Pty Ltd, Health World Limited, and Blackmores Limited, among others, were granted consents that imposed specific obligations. For example, Wyeth Consumer Healthcare Pty Ltd was permitted to supply Centrum Advance Tablets with an upper limit for lutein and lycopene content of 165% instead of the standard 120% (s 14(1)). This consent was given on the condition that the active ingredients did not exceed these specified limits, and it remained in effect until further notice. Similarly, Health World Limited was allowed to supply Ethical Nutrients Chromium Sugar Balance with an upper limit of R,S-alpha lipoic acid content at 130% rather than 120%, but only for a period of twelve months from 11 October 2010 (s 14A(1)). These consents required the companies to adhere strictly to the outlined conditions to ensure the therapeutic goods remained safe and effective for consumers. Failure to comply with the conditions set forth in these consents could result in legal consequences. The Therapeutic Goods Act 1989 provides for both civil and criminal penalties for non-compliance. Civil penalties may include fines up to a specified amount, as determined by the Act, for each instance of non-compliance. For example, supplying goods that do not meet the consent conditions could result in fines for the responsible entity. In more severe cases, criminal penalties may apply, including fines of up to AUD 1,000,000 and/or imprisonment for up to ten years for individuals, and fines of up to AUD 5,000,000 for bodies corporate. These penalties underscore the importance of adhering to the regulatory conditions outlined in the consents granted under sections 14 and 14A of the Act.